Trump Weighs 100% Semiconductor Tariffs to Reshore Manufacturing

President Donald Trump is pursuing a comprehensive reshoring strategy for critical manufacturing, beginning with a 100% tariff on branded and patented pharmaceutical imports effective October 1, 2025. This pharmaceutical measure exempts generic drugs and companies that have already broken ground on U.S. facilities, prompting companies like Novartis to announce five new domestic construction sites.

Following the pharmaceutical move, the administration is considering a 100% tariff on imported semiconductors. To incentivize domestic investment, the president is weighing a 1:1 production rule, requiring chipmakers to match the volume of imported chips with an equal amount of U.S. production to avoid duties. Trump has indicated that companies actively building U.S. facilities would be exempt from these charges. Major producers such as TSMC and Samsung Electronics would be significantly affected by these policies.

Parallel to direct chip tariffs, the U.S. Department of Commerce is drafting a plan to tax imported electronic devices—ranging from laptops to electric toothbrushes—based on the estimated value of the chips they contain. Preliminary figures suggest a 25% tariff on chip-related content, with lower 15% rates for goods from Japan and the European Union. White House spokesperson Kush Desai described the approach as a combination of tariffs, tax cuts, and deregulation intended to ensure national and economic security.

Industry groups and economists have warned that these measures could exacerbate inflation and increase consumer prices. The U.S. Chamber of Commerce and Intel noted that such tariffs could significantly raise the construction costs of domestic fabrication plants.